Staphylococcal infections in the era of MRSA

• Management of MRSA infection in the pediatric patient continues to rely on prompt diagnosis and localization of focus, and utilization of susceptibility data. • Drainage or debridement of abscess or necrotic material as well as knowledge of pharmacokinetic and pharmacodynamic data should guide appropriate therapy for specific infections. • Although vancomycin continues to be the cornerstone of therapy for MRSA infection in children, the increasing identification of strains having a vancomycin MIC at or beyond 1 mcg/mL may serve to change the scope of treatment for such infections in the future.